

Company Spotlight: Proteus Biomedical

Proteus Biomedical: Developing Intelligent Medical Solutions

Proteus Biomedical is a privately held company based in Redwood City, Ca. The firm is dedicated to developing intelligent medicine products internally and in partnership with device, pharmaceutical and biotechnology companies.



Intelligent medicine is an emerging field of advanced therapeutics that integrates electronics, sensors and wireless communications into pharmaceuticals and devices. Proteus has more than 200 patent filings in the field of intelligent medicine to date, and three products in development, including a program in Cardiac Resynchronization Therapy (CRT) with a world-leader in cardiovascular implantable devices.

Focus on Cardiac Diseases

Initially the company is focusing on therapies for the treatment of heart failure, developing devices that are designed to improve existing implantable (CRT) Systems. The first device is focused on eliminating extra-cardiac stimulation, an issue that complicates 10 to 20 percent of all CRT procedures. The company's second device in development utilizes the proprietary method of electronic tomography to provide real-time physiologic feedback to optimize CRT and pharmacologic therapy.

In addition therapeutic devices, the Proteus Raisin™ System is in development for optimizing pharmaceutical outcomes, initially in patients with heart failure. Proteus expects to initiate clinical trials of the Raisin System in late 2007.

Looking Forward

Proteus believes that intelligent medicine products offer the potential to transform the way chronic conditions are managed by providing physicians with medical intelligence that enables optimized, more cost-effective treatment for individual patients, and by providing patients with a deeper understanding of their individual response to treatment, offering peace of mind and increased control over their medical care. Future applications of intelligent medicine technology could include other cardiovascular diseases, respiratory diseases, metabolic and central nervous system disorders, and oncology.

Proteus management has a distinguished track record of developing and commercializing innovative medical therapies. The company's key investors include Adams Street Partners, Asset Management, The Carlyle Group, Essex Woodlands, Fletcher Spaght Ventures, L.P. (FSV), Kaiser Permanente Ventures, and Spring Ridge Ventures.

Notable Achievements

- Proof of concept feasibility of Electric Tomography has been demonstrated in heart failure patients and in multiple preclinical studies. Additional clinical trials are underway.
- Raisin System functionality has been demonstrated in multiple preclinical studies. Proteus expects to initiate clinical trials in late 2007.

Contact Information

Proteus Biomedical, Inc.
2600 Bridge Parkway, Suite 101
Redwood City, CA 94065
T: 650-632-4031
Email: astrand@proteusbiomed.com